Fate Therapeutics Inc (FATE)

2.77
0.07 2.46
NASDAQ : Health Care
Prev Close 2.84
Open 2.82
Day Low/High 2.73 / 2.89
52 Wk Low/High 1.46 / 7.29
Volume 104.83K
Avg Volume 378.60K
Exchange NASDAQ
Shares Outstanding 28.89M
Market Cap 83.51M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Fate Therapeutics Announces FDA Fast Track Designation For ProTmune™

Fate Therapeutics Announces FDA Fast Track Designation For ProTmune™

Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

8 Stocks Under $10 Making Big Moves Higher

8 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Fate Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ProTmune For Prevention Of Acute GvHD And CMV Infection

Fate Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ProTmune For Prevention Of Acute GvHD And CMV Infection

Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016

Fate Therapeutics To Present Strategy For The Development Of Off-the-Shelf Cancer Immunotherapies At ASH 2015

Fate Therapeutics To Present Strategy For The Development Of Off-the-Shelf Cancer Immunotherapies At ASH 2015

Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions

Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions

Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions

Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies